TCTMD: ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up
Saint Luke's Mid America Heart Institute is proud to have played a major role in the largest-ever randomized international trial to compare initial invasive surgical treatment vs. managing with medication and lifestyle changes for stable ischemic heart disease. The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial focused on evaluating survival and benefits to the patients quality of life.
“In patients with angina, shared decision-making should occur to align treatment with patients’ goals and preferences,” said Dr. John Spertus, director of health outcomes research at Saint Luke's Mid America Heart Institute and co-principal investigator for the ISCHEMIA quality of life analysis.
Read the full article from TCTMD: ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up